Comprehensive Analysis of the Prognostic Value and Immune Function of Immune Checkpoints in Stomach Adenocarcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Nie Y, Liu L, Liu Q, Zhu X. Identification of a metabolic-related gene signature predicting the overall survival for patients with stomach adenocarcinoma. Peer J. 2021;9:e10908. doi:10.7717/peerj.10908
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Liang LB, Huang XY, He H, Liu JY. Prognostic values of radiosensitivity genes and CD19 status in gastric cancer: a retrospective study using TCGA database. Pharmgenomics Pers Med. 2020;13:365–373.
   PubMed Web of Science ®Google Scholar
• Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol. 2016;22(8):2403–2414. doi:10.3748/wjg.v22.i8.2403
   PubMed Web of Science ®Google Scholar
• Chen H, Li K, Li Y, Xie P, He J, Zhang H. An integrative pan-cancer analysis of COPB1 based on data mining. Cancer Biomark. 2021;30(1):13–27. doi:10.3233/CBM-200398
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086. doi:10.1158/2159-8290.CD-18-0367
   PubMed Web of Science ®Google Scholar
• Huang X, Tang T, Wang X, Bai X, Liang T. Calreticulin couples with immune checkpoints in pancreatic cancer. Clin Transl Med. 2020;10(1):36–44. doi:10.1002/ctm2.10
   PubMed Web of Science ®Google Scholar
• Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1/PD-L1 immune checkpoint: potential target for cancer therapy. J Cell Physiol. 2019;234(2):1313–1325. doi:10.1002/jcp.27172
   PubMed Web of Science ®Google Scholar
• Miao YR, Thakkar KN, Qian J, et al. Neutralization of PD-L2 is essential for overcoming immune checkpoint blockade resistance in ovarian cancer. Clin Cancer Res. 2021;27:4435–4448. doi:10.1158/1078-0432.CCR-20-0482
   PubMed Web of Science ®Google Scholar
• Fang J, Chen F, Liu D, Gu F, Chen Z, Wang Y. Prognostic value of immune checkpoint molecules in breast cancer. Biosci Rep. 2020;40:BSR20201054.
   PubMed Web of Science ®Google Scholar
• D’Errico M, de Rinaldis E, Blasi MF, et al. Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. Eur J Cancer. 2009;45:461–469. doi:10.1016/j.ejca.2008.10.032
   PubMed Web of Science ®Google Scholar
• Wang Q, Wen YG, Li DP, et al. Upregulated INHBA expression is associated with poor survival in gastric cancer. Med Oncol. 2012;29(1):77–83. doi:10.1007/s12032-010-9766-y
   PubMed Web of Science ®Google Scholar
• Liang F, Liang H, Li Z, Huang P. JAK3 is a potential biomarker and associated with immune infiltration in kidney renal clear cell carcinoma. Int Immunopharmacol. 2020;86:106706. doi:10.1016/j.intimp.2020.106706
   PubMed Web of Science ®Google Scholar
• Zeng Q, Sun S, Li Y, Li X, Li Z, Liang H. Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in the renal cell carcinoma microenvironment. Front Oncol. 2019;9:1555. doi:10.3389/fonc.2019.01555
   PubMed Web of Science ®Google Scholar
• Zhou L, Li Y, Li Z, Huang Q. Mining therapeutic and prognostic significance of STATs in renal cell carcinoma with bioinformatics analysis. Genomics. 2020;112:4100–4114. doi:10.1016/j.ygeno.2020.06.032
   PubMed Web of Science ®Google Scholar
• Adda L, Batteux B, Saidak Z, et al. Effect of immune checkpoint inhibitor-induced rheumatic and musculoskeletal disorders on overall survival. Joint Bone Spine. 2021;88(4):105168. doi:10.1016/j.jbspin.2021.105168
   PubMed Web of Science ®Google Scholar
• Paderi A, Giorgione R, Giommoni E, et al. Association between immune related adverse events and outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Cancers. 2021;13:860.
   PubMed Web of Science ®Google Scholar
• Grandal B, Mangiardi-Veltin M, Laas E, et al. PD-L1 expression after neoadjuvant chemotherapy in triple-negative breast cancers is associated with aggressive residual disease, suggesting a potential for immunotherapy. Cancers. 2021;13:746.
   PubMed Web of Science ®Google Scholar
• Xiao C, Hong H, Yu H, et al. MiR-340 affects gastric cancer cell proliferation, cycle, and apoptosis through regulating SOCS3/JAK-STAT signaling pathway. Immunopharmacol Immunotoxicol. 2018;40(4):278–283. doi:10.1080/08923973.2018.1455208
   PubMed Web of Science ®Google Scholar
• Garg AD, Agostinis P. Cell death and immunity in cancer: from danger signals to mimicry of pathogen defense responses. Immunol Rev. 2017;280:126–148. doi:10.1111/imr.12574
   PubMed Web of Science ®Google Scholar
• Yin Z, Bai L, Li W, Zeng T, Tian H, Cui J. Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy. J Exp Clin Cancer Res. 2019;38(1):403. doi:10.1186/s13046-019-1409-3
   PubMed Web of Science ®Google Scholar
• Inaguma S, Lasota J, Czapiewski P, et al. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness. J Pathol. 2020;250(2):205–216. doi:10.1002/path.5361
   PubMed Web of Science ®Google Scholar
• Fan Y, Li T, Xu L, Kuang T. Comprehensive analysis of immunoinhibitors identifies LGALS9 and TGFBR1 as potential prognostic biomarkers for pancreatic cancer. Comput Math Methods Med. 2020;2020:6138039. doi:10.1155/2020/6138039
   PubMed Web of Science ®Google Scholar
• Li Y, Lu Z, Che Y, et al. Immune signature profiling identified predictive and prognostic factors for esophageal squamous cell carcinoma. Oncoimmunology. 2017;6:e1356147. doi:10.1080/2162402X.2017.1356147
   PubMed Web of Science ®Google Scholar
• Alexander PG, McMillan DC, Park JH. A meta-analysis of CD274 (PD-L1) assessment and prognosis in colorectal cancer and its role in predicting response to anti-PD-1 therapy. Crit Rev Oncol Hematol. 2021;157:103147. doi:10.1016/j.critrevonc.2020.103147
   PubMed Web of Science ®Google Scholar
• Li F, Sun Y, Huang J, Xu W, Liu J, Yuan Z. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indicators of gastric cancer prognosis. Cancer Med. 2019;8(17):7330–7344. doi:10.1002/cam4.2596
   PubMed Web of Science ®Google Scholar
• Lee SE, Shin AR, Sohn HJ, Cho HI, Kim TG. T cells modified with CD70 as an alternative cellular vaccine for antitumor immunity. Cancer Res Treat. 2020;52(3):747–763. doi:10.4143/crt.2019.721
   PubMed Web of Science ®Google Scholar